---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-23-000022"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:29:13.341218+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q4 2022 net loss $72M; ZORYVE revenue $3M in first full quarter

## Summary
- Net product revenue for ZORYVE was $3.0M in Q4 2022, first full quarter since August 2022 launch.
- Net loss of $72.0M ($1.18/share) in Q4 2022 vs $71.3M ($1.42/share) in Q4 2021.
- Full-year 2022 net loss $311.5M ($5.66/share) vs $206.4M ($4.18/share) in 2021.
- Cash, equivalents, and marketable securities $410.8M as of Dec 31, 2022.
- Positive Phase 3 atopic dermatitis results; NDA submitted for roflumilast foam in seborrheic dermatitis.

## SEC filing metadata
- accession: 0001787306-23-000022
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/0001787306-23-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/arqt-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-23-000022
- JSON: https://secwatch.observer/filing/0001787306-23-000022.json
- Plain text: https://secwatch.observer/filing/0001787306-23-000022.txt

## Key facts
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported the year ended December 31, 2022 results: revenue $3.7 million.
  - Period: the year ended December 31, 2022
  - Revenue: $3.7 million
  - Result: reported results
  source text: Net product revenues for the year ended December 31, 2022 were $3.7 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/0001787306-23-000022-index.htm
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported the quarter ended December 31, 2022 results: revenue $3.0 million.
  - Period: the quarter ended December 31, 2022
  - Revenue: $3.0 million
  - Result: reported results
  source text: Net product revenues for the quarter ended December 31, 2022 related to sales of ZORYVE were $3.0 million driven by unit demand.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/0001787306-23-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.